An Open-Label, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-42847922 in Adult Participants
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Seltorexant (Primary)
- Indications Alzheimer's disease; Insomnia; Major depressive disorder; Renal impairment; Sleep apnoea syndrome
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 31 Jan 2023 Status changed from recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 23 May 2022 to 12 Dec 2022.
- 20 Jul 2022 Planned primary completion date changed from 2 May 2022 to 12 Dec 2022.